Biofarm Bucure Total Assets
Biofarm Bucure total assets. Based on the latest financial reports, Biofarm Bucure (BIO) holds total assets worth RON634.39 Million RON (≈ $145.67 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash flow conversion of Biofarm Bucure for how efficiently the company converts equity into cash flow.
Total Assets of Biofarm Bucure (2019–2025)
Total assets of Biofarm Bucure from 2019 to 2025. This chart illustrates how Biofarm Bucure's total assets have evolved over time, based on quarterly financial data. See today's stock price for Biofarm Bucure for real-time trading data and today's change.
Biofarm Bucure - Asset Composition Analysis
Biofarm Bucure Total Assets Breakdown (September 2025)
Biofarm Bucure total assets breakdown as of September 2025. Biofarm Bucure's total assets of RON634.39 Million consist of 63.7% current assets and 36.3% non-current assets. Explore BIO working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (RON) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RON0.00 | 18.2% |
| Accounts Receivable | RON170.23 Million | 26.8% |
| Inventory | RON63.67 Million | 10.0% |
| Property, Plant & Equipment | RON0.00 | 0.0% |
| Intangible Assets | RON0.00 | 0.0% |
| Goodwill | RON0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Biofarm Bucure's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biofarm Bucure's current assets represent 63.7% of total assets in 2025, an increase from 58.5% in 2019.
- Cash Position: Cash and equivalents constituted 18.2% of total assets in 2025, down from 26.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 26.8% of total assets.
Biofarm Bucure Competitors by Total Assets
Key competitors of Biofarm Bucure based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Turk Ilac ve Serum Sanayi AS
IS:TRILC
|
Turkey | TL6.12 Billion |
|
Wockhardt Limited
NSE:WOCKPHARMA
|
India | Rs81.35 Billion |
|
PharmaBlock Sciences Nanjing Inc Class A
SHE:300725
|
China | CN¥5.38 Billion |
|
AptaBio Therapeutics Inc
KQ:293780
|
Korea | ₩67.12 Billion |
|
Canopy Growth Corp
NASDAQ:CGC
|
USA | $1.10 Billion |
|
Zhejiang Nhu Co Ltd
SHE:002001
|
China | CN¥47.45 Billion |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
|
Turkey | TL70.69 Billion |
|
Beijing Science Sun Pharmaceutical Co Ltd
SHE:300485
|
China | CN¥3.36 Billion |
Biofarm Bucure - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.80 | 4.34 | 3.26 |
| Quick Ratio | 4.04 | 3.64 | 2.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | RON319.95 Million | RON252.84 Million | RON188.38 Million |
Biofarm Bucure - Advanced Valuation Insights
This section examines the relationship between Biofarm Bucure's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.61 |
| Latest Market Cap to Assets Ratio | 0.49 |
| Asset Growth Rate (YoY) | 14.2% |
| Total Assets | RON634.39 Million |
| Market Capitalization | $309.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biofarm Bucure's assets below their book value (0.49x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Biofarm Bucure's assets grew by 14.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biofarm Bucure (2019–2025)
The table below shows the annual total assets of Biofarm Bucure from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | RON634.39 Million ≈ $145.67 Million |
+14.21% |
| 2024-09-30 | RON555.48 Million ≈ $127.55 Million |
+12.49% |
| 2023-09-30 | RON493.81 Million ≈ $113.39 Million |
+5.85% |
| 2022-09-30 | RON466.54 Million ≈ $107.12 Million |
+11.40% |
| 2021-09-30 | RON418.78 Million ≈ $96.16 Million |
+12.46% |
| 2020-09-30 | RON372.38 Million ≈ $85.50 Million |
+7.43% |
| 2019-09-30 | RON346.62 Million ≈ $79.59 Million |
-- |
About Biofarm Bucure
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescr… Read more